H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Halozyme (HALO) to $75 from $72 and keeps a Buy rating on the shares following the Q2 report. The company increased its fiscal 2025 guidance for the third time this year after reporting another robust quarter, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme upgraded to Overweight from Equal Weight at Morgan Stanley
- Halozyme Therapeutics Reports Strong Q2 2025 Results
- Positive Outlook and Strong Performance Drive Buy Rating for Halozyme
- Halozyme reports Q2 non-GAAP EPS $1.54, consensus $1.23
- Halozyme raises FY25 non-GAAP EPS view to $6.00-$6.40 from $5.30-$5.70